A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection Versus Erbitux in Healthy Male Subjects (BT-HC034S-101)
A Phase I, Randomized, Double-Blind, Positive-Controlled, Parallel-Group Pharmacokinetic Clinical Study of Cetuximab Injection Versus Erbitux in Healthy Male Subjects
A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection versus Erbitux in Healthy Male Subjects
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Xiaoai He
- 電話番号:+86-1500-897-1099
- メール:15008971099@126.com
研究場所
-
-
Hainan
-
Haikou、Hainan、中国、570208
- 募集
- Haikou People's Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Provide written informed consent prior to study entry and fully understand the study content, procedures and potential adverse reactions;
- Be able to complete the study as required by the study protocol;
- Have no fertility plan (including sperm donation) in the subsequent 6 months and agree to use effective contraception;
- Be healthy male subjects aged 18-46 years (inclusive); body weight ≥50 kg; body mass index (BMI, calculated as weight [kg]/height² [m²]) ranging from 18.0 to 28.5 kg/m² (inclusive).
Exclusion Criteria:
- Provide written informed consent prior to study entry and fully understand the study content, procedures and potential adverse reactions;
- Be able to complete the study as required by the study protocol;
- Have no fertility plan (including sperm donation) in the subsequent 6 months and agree to use effective contraception;
- Be healthy male subjects aged 18-46 years (inclusive); body weight ≥50 kg; body mass index (BMI, calculated as weight [kg]/height² [m²]) ranging from 18.0 to 28.5 kg/m² (inclusive).
Exclusion Criteria:
- Subjects with allergic diathesis, or history of food/drug allergy within recent 4 weeks, especially hypersensitivity to any component of investigational product or excipients;
- Blood donation or substantial blood loss (>200 mL) within 3 months, or platelet donation within 2 weeks prior to investigational product administration;
- Major surgery within 6 months prior to first dosing, or planned surgery during study;
- Hereditary bleeding tendency, coagulation disorders, or history of thrombosis / hemorrhagic diseases;
- Prior treatment with EGFR-targeted agents;
- Use of prescription / over-the-counter drugs or nutritional supplements within 5 half-lives of the product OR within 2 weeks before study drug administration (whichever is longer). Discontinue traditional Chinese medicinal supplements 28 days prior to study drug administration, except for topical products with no systemic absorption.
- Clinically significant abnormalities as assessed by investigator in vital signs (SBP <90 mmHg or >140 mmHg; DBP >90 mmHg), physical examination, ECG (resting heart rate <50 or >100 beats/min), laboratory tests (blood biochemistry, CBC, urinalysis, coagulation);
- Presence of any investigator-identified clinically significant disease, including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, neoplastic, pulmonary, immune, psychiatric, cardiovascular and cerebrovascular disorders;
- History of hepatitis B, hepatitis C, AIDS, syphilis, or clinically significant abnormality in ≥1 item of infectious disease four-panel screening;
- Alcohol intake ≥14 units/week within 3 months pre-screening (1 unit = 285 mL beer, 25 mL 40%-ABV spirits, 150 mL 12%-ABV wine); alcohol-containing products consumed within 24 h prior to study drug dosing; positive alcohol breath test at screening;
- Cigarette smoking ≥5 cigarettes/day within 3 months pre-screening;
- Drug abuse history within 5 years, illicit drug use within 3 months before screening, habitual use of any medicines (including herbal medicines), or positive urine drug screen.
- Participation in any drug clinical trial with investigational product administration, or medical device trial receiving device treatment, or use of drugs of the same class within 3 months prior to screening;
- Receipt of live-attenuated vaccines within 14 days prior to first dosing, or planned live-attenuated vaccination during study;
- Intolerance to venipuncture blood collection, or history of needle-phobia or hematophobia;
- Any subject who, in investigator's judgment, may be unable to provide informed consent or follow the protocol; whose participation may bias study results or endanger subject safety; or otherwise considered unsuitable for study enrollment.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:HC034S
|
Single intravenous infusion. Study participants shall be pre-medicated with antihistamines and corticosteroids no less than 1 h before the first HC034S injection infusion. Administer intravenously by infusion pump at 250 mg/m² (body surface area), infusion duration: 2 h ± 10 min. |
|
アクティブコンパレータ:China-sourced Erbitux®
|
Single intravenous infusion. Study participants shall be pre-medicated with antihistamines and corticosteroids no less than 1 h before the first cetuximab injection infusion. Administer intravenously by infusion pump at 250 mg/m² (body surface area), infusion duration: 2 h ± 10 min. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Area under the serum concentration-time curve from time 0 to infinity (AUC0-∞)
時間枠:Up to Day 29
|
Up to Day 29
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
quantifiable concentration (AUC₀-t)
時間枠:Up to Day 29
|
Up to Day 29
|
|
Maximum serum concentration (Cmax)
時間枠:Up to Day 29
|
Up to Day 29
|
|
Time to reach maximum serum concentration (Tmax)
時間枠:Up to Day 29
|
Up to Day 29
|
|
Total clearance (CL)
時間枠:Up to Day 29
|
Up to Day 29
|
|
Terminal elimination half-life (t1/2)
時間枠:Up to Day 29
|
Up to Day 29
|
|
Apparent volume of distribution (Vd)
時間枠:Up to Day 29
|
Up to Day 29
|
|
Apparent terminal elimination rate constant (λz)
時間枠:Up to Day 29
|
Up to Day 29
|
|
Percentage of the area-under-the-curve extrapolated to infinity (AUC_%Extrap)
時間枠:Up to Day 29
|
Up to Day 29
|
|
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) following study drug administration, including electrocardiograms (ECG), laboratory test parameters, physical examinations, and vital signs.
時間枠:Up to Day 29
|
Up to Day 29
|
|
Positive incidence, titer and duration of anti-drug antibodies (ADA) and neutralizing antibodies (NAb)
時間枠:Up to Day 29
|
Up to Day 29
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- HC034S-101
- BT-HC034S-101 (その他の識別子:Shanghai Hongcheng Pharmaceutical Co., Ltd.)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。